|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nygren P and Glimelius B; SBU-group:
Swedish Council on Technology Assessment in Health Care: The
Swedish Council on Technology Assessment in Health Care (SBU)
report on Cancer Chemotherapy - Project objectives, the working
process, key definitions and general aspects on cancer trial
methodology and interpretation. Acta Oncol. 40:155–165. 2001.
View Article : Google Scholar
|
|
3
|
Impicciatore G, Sancilio S, Miscia S and
Di Pietro R: Nutlins and ionizing radiation in cancer therapy. Curr
Pharm Des. 16:1427–1442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang S, Wang L, Liu H, Zhao G and Ming L:
Enhancement of recombinant myricetin on the radiosensitivity of
lung cancer A549 and H1299 cells. Diagn Pathol. 9:682014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dumont F, Altmeyer A and Bischoff P:
Radiosensitising agents for the radiotherapy of cancer: novel
molecularly targeted approaches. Expert Opin Ther Pat. 19:775–799.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bischoff P, Altmeyer A and Dumont F:
Radiosensitising agents for the radiotherapy of cancer: advances in
traditional and hypoxia targeted radiosensitisers. Expert Opin Ther
Pat. 19:643–662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walensky LD: BCL-2 in the crosshairs:
tipping the balance of life and death. Cell Death Differ.
13:1339–1350. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang TM, Barbone D, Fennell DA and
Broaddus VC: Bcl-2 family proteins contribute to apoptotic
resistance in lung cancer multi-cellular spheroids. Am J Respir
Cell Mol Biol. 41:14–23. 2009. View Article : Google Scholar :
|
|
10
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kirkin V, Joos S and Zörnig M: The role of
Bcl-2 family members in tumorigenesis. Biochim Biophys Acta.
1644:229–249. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soini Y, Kinnula V, Kaarteenaho-Wiik R,
Kurttila E, Linnainmaa K and Pääkko P: Apoptosis and expression of
apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in
malignant mesothelioma. Clin Cancer Res. 5:3508–3515.
1999.PubMed/NCBI
|
|
13
|
Karczmarek-Borowska B, Filip A,
Wojcierowski J, et al: Estimation of prognostic value of Bcl-xL
gene expression in non-small cell lung cancer. Lung Cancer.
51:61–69. 2006. View Article : Google Scholar
|
|
14
|
Gottlieb E, Vander Heiden MG and Thompson
CB: Bcl-x(L) prevents the initial decrease in mitochondrial
membrane potential and subsequent reactive oxygen species
production during tumor necrosis factor alpha-induced apoptosis.
Mol Cell Biol. 20:5680–5689. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guichard SM, Hua ML, Kang P, Macpherson JS
and Jodrell DI: Short hairpin RNAs targeting Bcl-xL modulate
senescence and apoptosis following SN-38 and irinotecan exposure in
a colon cancer model. Cancer Chemother Pharmacol. 60:651–660. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu H, Guo W, Zhang L, et al: Bcl-xL small
interfering RNA suppresses the proliferation of
5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther.
4:451–456. 2005.PubMed/NCBI
|
|
17
|
Nita ME, Ono-Nita SK, Tsuno N, et al:
Bcl-X(L) antisense sensitizes human colon cancer cell line to
5-fluorouracil. Jpn J Cancer Res. 91:825–832. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Varin E, Denoyelle C, Brotin E, et al:
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell
death in mesothelioma cells highly refractory to conventional
chemotherapy. Carcinogenesis. 31:984–993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lei X, Huang Z, Zhong M, Zhu B, Tang S and
Liao D: Bcl-xL small interfering RNA sensitizes cisplatin-resistant
human lung adenocarcinoma cells. Acta Biochim Biophys Sin
(Shanghai). 39:344–350. 2007. View Article : Google Scholar
|
|
20
|
Yang J, Sun M, Zhang A, Lv C, De W and
Wang Z: Adenovirus-mediated siRNA targeting Bcl-xL inhibits
proliferation, reduces invasion and enhances radiosensitivity of
human colorectal cancer cells. World J Surg Oncol. 9:1172011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uprichard SL: The therapeutic potential of
RNA interference. FEBS Lett. 579:5996–6007. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sui G, Soohoo C, Affar el B, et al: A DNA
vector-based RNAi technology to suppress gene expression in
mammalian cells. Proc Natl Acad Sci USA. 99:5515–5520. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chetty C, Bhoopathi P, Rao JS and Lakka
SS: Inhibition of matrix metalloproteinase-2 enhances
radiosensitivity by abrogating radiation-induced FoxM1-mediated
G2/M arrest in A549 lung cancer cells. Int J Cancer. 124:2468–2477.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baumann M, Stamatis G and Thomas M:
Therapy of localized non-small cell lung cancer (take home
messages). Lung Cancer. 33(Suppl 1): S47–S49. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Duchesne GM: Fundamental bases of combined
therapy in lung cancer: cell resistance to chemotherapy and
radiotherapy. Lung Cancer. 10(Suppl 1): S67–S72. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gressen EL and Curran WJ:
Hyperfractionated radiotherapy for lung cancer. Curr Oncol Rep.
2:71–75. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Llambi F and Green DR: Apoptosis and
oncogenesis: give and take in the BCL-2 family. Curr Opin Genet
Dev. 21:12–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Streffer JR, Rimner A, Rieger J, Naumann
U, Rodemann HP and Weller M: BCL-2 family proteins modulate
radiosensitivity in human malignant glioma cells. J Neurooncol.
56:43–49. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Masui T, Hosotani R, Ito D, et al: Bcl-xL
antisense oligonucleotides coupled with antennapedia enhances
radiation-induced apoptosis in pancreatic cancer. Surgery.
140:149–160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang R, Lin F, Wang X, et al: Suppression
of Bcl-xL expression by a novel tumor-specific RNA interference
system inhibits proliferation and enhances radiosensitivity in
prostatic carcinoma cells. Cancer Chemother Pharmacol. 61:943–952.
2008. View Article : Google Scholar
|
|
32
|
Lei XY, Zhong M, Feng LF, Zhu BY, Tang SS
and Liao DF: Bcl-xL small interfering RNA enhances sensitivity of
Hepg2 hepatocellular carcinoma cells to 5-fluorouracil and
hydroxycamptothecin. Acta Biochim Biophys Sin (Shanghai).
38:704–710. 2006. View Article : Google Scholar
|
|
33
|
Zhang J and Hua ZC: Targeted gene
silencing by small interfering RNA-based knock-down technology.
Curr Pharm Biotechnol. 5:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Matsuyama Y, Yamayoshi A, Kobori A and
Murakami A: Functional regulation of RNA-induced silencing complex
by photoreactive oligonucleotides. Bioorg Med Chem. 22:1003–1007.
2014. View Article : Google Scholar : PubMed/NCBI
|
